Table 1 Demographic and clinical characteristics
From: The impact of the duration of the integrated disease management program on COPD-related outcomes
|  | N = 3771 |
|---|---|
Age, mean (SD) | 71.47 ± 9.7 |
Age category (year), N (%) | |
 < 50 | 57 (1.5) |
 51–60 | 362 (9.6) |
 61–70 | 1173 (31.2) |
 71–80 | 1343 (35.7) |
 > 80 | 836 (22.2) |
Gender, n (%) | |
 Female | 320 (8.4) |
 Male | 3451 (91.5) |
Charlson comorbidities index, mean (SD) | 2.26 ± 1.53 |
CCI category, n (%) | |
 0–1 | 94 (2.4) |
 2 | 2322 (61.5) |
 ≥ 3 | 1355 (36) |
BMI (kg/m2), mean (SD) | 24.93 ± 46.55 |
BMI category (kg/m2), n (%) | |
 <18.5 | 276 (7.2) |
 18.5 ≤ BMI < 24 | 1768 (46.8) |
 ≥ 24 | 1727 (45.9) |
Smoking status, n (%) | |
 Never smoker | 504 (13.5) |
 Former smoker | 2240 (59.4) |
 Current smoker | 1027 (27.3) |
Accreditation level, n (%) | |
 Medical center | 1255 (33.3) |
 Regional hospital | 1800 (47.7) |
 District hospital | 562 (15) |
 Clinics | 154 (4.2) |
Branch, n (%) | |
 Taipei | 1182 (31.2) |
 Northern | 457 (12) |
 Central | 944 (24.9) |
 Southern | 682 (18) |
 Kao-Ping | 437 (11.7) |
 Eastern | 69 (1.8) |
Baseline FEV1 (L), mean (SD) | 1.46 ± 0.56 |
Baseline FEV% (% of predicted value), mean (SD) | 63.37 ± 22.08 |
Baseline FEV1/FVC (%), mean (SD) | 56.67 ± 11.48 |
Baseline airflow limitation, n (%) | |
 ≥ 80% predicted | 841 (22.2) |
 50–79% predicted | 1862 (49.5) |
 30–49% predicted | 888 (23.4) |
 < 30% predicted | 180 (4.8) |
Baseline mMRC, mean (SD) | 1.53 ± 0.91 |
Baseline mMRC category, n (%) | |
 0 | 469 (12.3) |
 1 | 1441 (38.1) |
 2 | 1313 (34.8) |
 3 | 505 (13.5) |
 4 | 43 (1.2) |
Baseline CAT, mean (SD) | 10.49 ± 6.47 |
Baseline CAT category, n (%) | |
 0–10 | 2162 (57.3) |
 11–20 | 1295 (34.2) |
 21–30 | 296 (7.8) |
 31–40 | 18 (0.6) |
Acute exacerbation in previous 1Â year, n (%) | |
 < 2 | 3239 (85.8) |
 ≥ 2 | 532 (14.1) |
Baseline GOLD risk group, n (%) | |
 A | 1136 (30) |
 B | 1715 (45.6) |
 C | 314 (8.4) |
 D | 606 (16.2) |
Wheezing at baseline, n (%) | |
 No | 3089 (81.9) |
 Yes | 682 (18) |
Naïve-treatment patients at baseline, n (%) | |
 No | 3615 (96) |
 Yes | 156 (4.2) |
Inhaler therapy at baseline, n (%) | |
 Without inhaler prescription | 22 (0.6) |
 SABD | 43 (1.1) |
 Mono therapy | 841 (22.3) |
 Dual therapy | 2006 (53.2) |
 Triple therapy | 859 (22.8) |
Switch in COPD medication over the course of the program, n (%) | |
 No | 2525 (67.0) |
 Yes | 1246 (33.0) |